Clinical Trial

Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.

Study acronym: PHYTASE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 2, 2026 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the present postdoctoral research is to evaluate the acceptability and adherence of two dietary supplements containing microbial phytase, Goodphyte IB Defense and Goodphyte Immunity, in adult individuals with chronic diseases, namely Idiopathic Inflammatory Bowel Diseases (IIBD)-that is, Crohn's disease (CD) or Ulcerative Colitis (UC)-Arterial Hypertension (AH), Anemia (AN), or Multiple Sclerosis (MS). Secondarily, this study will investigate potential changes in iron and zinc absorption following phytase supplementation in these individuals and, consequently, possible changes in their quality of life.
Trial Details
NCT Number NCT07380022
Lead Sponsor University of Thessaly
Conditions IBD, Hypertension (HTN), Multiple Sclerosis, Anemia, Colitis Ulcerative
Enrollment 100 participants
Start Date 2025-07-09
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-02